The company said worldwide revenue for Q2 2024 rose to $11.30 billion, an increase of 36%. It cited a 27% increase in volume and a 10% rise in realized prices, and said foreign exchange rates reduced revenue by 1%.

1. 01

   The company said worldwide revenue for Q2 2024 rose to $11.30 billion, an increase of 36%. It cited a 27% increase in volume and a 10% rise in realized prices, and said foreign exchange rates reduced revenue by 1%.

2. 02

   The company said Mounjaro revenue for Q2 was $3.09 billion ($979.7 million in the same period a year earlier), and U.S. Zepbound revenue was $1.24 billion. It estimated that channel stocking in U.S. Mounjaro and Zepbound sales totaled high teens to mid-mid-20s as a percent of U.S. sales.

3. 03

   The company said reported net income for Q2 2024 was $2.97 billion, reported diluted EPS was $3.28, and non-GAAP EPS was $3.92. It explained that the asset impairment, restructuring and other special charges of $435.0 million were related to anticipated litigation payments.

4. 04

   The company raised its full-year 2024 revenue guidance by $3.0 billion to $45.4 billion to $46.6 billion (from $42.4 billion to $43.6 billion). It set reported EPS guidance at $15.10 to $15.60 and non-GAAP EPS guidance at $16.10 to $16.60.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.